Of course, sno, its more complicated and so more risk. What a surprise that the design you complained about not getting posted, doesnt meet with your approval.LOL You are getting a little too predictable.
You can count on the other endpoints only working to the advantage of rgrx. Ora and the koreans are not here to make things more "complicated and risky" for eventual approval.
So examine to your hearts content sno, but in the end you are not qualified to reach any reasonable conclusion in regard to endpoints. The huge day in scln today is a reminder of that.
Hey B7, you mention tb4 as a possible new drug to help "alleviate symptoms". But the real game changer with rgrx's drug is that not only will it help alleviate, it will be the one and only drug that can say it can help heal dry eye; when the total corneal staining endpoint is hit. Current drug on the market can not say that, and the new billion dollar drug by Shire can certainly not say that. Add in NO adverse side effects, and TB4 will have a big competitive advantage. 40 cents......................give me a break
You dult. I am tired of trying to explain the obvious to you. My point was that here we have another deep pocketed, visionary, who validates the technology by using it himself along with his son. EECP or ECP works and it was up to Ma, with the GE money in hand, to do the necessary trials years ago. Instead, he has sold out to the bankers and Castle.